Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus ...

As2O3 has been demonstrated to inhibit HCC development, while the effect of immune-regulation in HCC remains elusive. Here, we aim to investigate the immune-regulatory mechanism of As2O3-induced HCC ...